Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01633541
Other study ID # UMCC 2010.101
Secondary ID HUM00043975
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2012
Est. completion date November 6, 2021

Study information

Verified date July 2023
Source University of Michigan Rogel Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate a new treatment approach for adults with advanced laryngeal cancer: induction chemotherapy with platinum and docetaxel plus AT-101. AT-101 is an investigational drug for the treatment of advanced cancer. It is hoped that the combination of this chemotherapy regimen will allow cancer patients to keep their voice box and to improve/maintain voice-related quality of life. The ultimate goal of this study is to prevent the surgery to remove subjects voice box.


Description:

Published data demonstrate equal efficacy and improved quality of life when platinum and a taxane were compared with platinum and 5-Fluorouracil [31]. Additionally, weekly cisplatin regimens (30-40 mg/m2) with radiotherapy appear to be equally efficacious and better tolerated than standard high-dose cisplatin (100 mg/ m2) regimens with radiation therapy for locally advanced SCCHN [32] The investigators will thus attempt to reduce toxicity from induction chemotherapy with the use of docetaxel/cisplatin (or carboplatin) (TP) in place of our previously used standard regimen of cisplatin and 5-fluorouracil (PF) and administer weekly cisplatin (or carboplatin) with radiation for those patients who are responders to induction therapy. Finally, Phase I/II testing of the small molecule inhibitor, AT-101, has recently been completed, and suggests activity in solid tumors when combined with cytotoxic agents. Since the investigators have achieved such high survival rates with our treatment selection approach in laryngeal cancer, our ultimate goal is to reduce the rate of salvage laryngectomy which should improve quality of life. The investigators hypothesize that specific inhibition of Bcl-2/Bcl-xL function can increase response rates to neoadjuvant chemotherapy and decrease the need for salvage laryngectomy. Hence, the investigators propose this study: the treatment of patients with advanced SCC of the larynx with one cycle of platinum plus docetaxel with AT-101, followed by chemoradiotherapy for those responding to this induction regimen and reserving total laryngectomy for those who are non-responders.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date November 6, 2021
Est. primary completion date November 6, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients must have pathologically confirmed, previously untreated, resectable, squamous cell carcinoma of the larynx or hypopharynx. - Disease must be Stage III or IV - Tumor must be potentially surgically resectable and curable with conventional surgery and radiation therapy - Patients must undergo pre-treatment endoscopic tumor staging and CT scanning - ECOG Performance status 0-1 - Adequate WBC (white blood cell), granulocyte and platelet counts - Creatinine clearance of = 60cc/min for cisplatin candidates and = 30 cc/min for carboplatin candidates - Adequate bilirubin, AST (aspartate aminotransferase), and ALT (alanine transaminase) function Exclusion Criteria: - Prior head and neck malignancy or history of other prior non-head and neck malignancy within the past 3 years - Prior head and neck radiation or prior chemotherapy. - Documented evidence of distant metastases - Active infection - Pregnancy or lactation - Any medical or psychiatric illness which in the opinion of the principal investigator would compromise the patient's ability to tolerate this treatment - Patients residing in prison - Patients with psychiatric/ social situations that would limit compliance with study requirements - Patients with Grade > 2 peripheral neuropathy - History of severe hypersensitivity reaction to docetaxel - Class 3 or 4 cardiac disease - Unstable angina or history of myocardial ischemia within prior 6 months - Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, partial or complete small bowel obstruction - Prior use of gossypol or AT-101, or known hypersensitivity to gossypol or AT-101 - Patients taking any other concurrent approved or investigational anti-cancer therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
AT-101
Patients will receive AT-101 40 mg orally two times a day.
Docetaxel
Docetaxel (Taxotere) 75 mg/m2
Cisplatin
Cisplatin 100 mg/m2
Carboplatin
Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg

Locations

Country Name City State
United States University of Michigan Comprehensive Cancer Center Ann Arbor Michigan

Sponsors (1)

Lead Sponsor Collaborator
University of Michigan Rogel Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Patients Alive and Free From Indication for Laryngectomy Three Months Post Treatment The primary clinical objective of this trial is to compare the larynx preservation rates in a treatment paradigm that uses induction chemotherapy plus AT-101 to select patients for either concurrent chemoradiation or surgery. Organ preservation rate, defined as alive and free from indication for laryngectomy three months post treatment, was chosen as the primary endpoint because it provides evidence to fully characterize clinically the effect of the treatment strategy Up to 3 months after end of treatment
Primary Progression-free Survival Time from randomization to the time of first indication of local failure or metastases. Estimated non-parametrically using the Kaplan-Meier method. Up to 3 years after randomization
Primary Overall Response Rate (ORR) ORR (Complete Response [CR] plus Partial Response [PR]) to induction chemotherapy with platinum and docetaxel plus AT-101 following one and/or two cycles in patients with advanced laryngeal cancer. Up to approximately 60 days
Primary Percentage of Patients Experiencing Grade 3 or Higher Adverse Events. Toxicities will be evaluated using the Common Terminology Criteria for Adverse Events (CTCAE), version 3. Up to 3 years after end of treatment
Secondary Head and Neck Related Quality of Life (QOL) University of Michigan Head and Neck Quality of Life Instrument (HN-QOL) will be administered prior to treatment (i.e. pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated). Scale is 0-100 with high scores indicating a better outcome. Up to 28 months post treatment
Secondary Voice Related QOL The University of Michigan Voice Related Quality of Life Measure (V-RQOL) will be administered prior to treatment (i.e. pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated). Scale is 0-50 (10 items scale 1-5) with high scores indicating a worse outcome. Up to 28 months post treatment
Secondary Functional Assessment QOL University of Michigan Head and Neck Quality of Life Instrument (HN-QOL) will be administered prior to treatment (i.e. pre-induction chemotherapy) and at 6 months, 12 months, and 24 months (+/- 4 months) after completion of chemo-RT or surgery-RT (or surgery-chemoRT, as indicated). Scale is 0-100 with high scores indicating a better outcome. EATING Domain is reported here as a functional assessment. Up to 28 months post treatment
See also
  Status Clinical Trial Phase
Completed NCT01089803 - Observational Study of Swallowing Function After Treatment of Advanced Laryngeal Cancer N/A
Completed NCT00026975 - Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients Phase 2
Completed NCT01435252 - A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Phase 2
Recruiting NCT04174950 - Perioperative ERAS Based Nursing Intervention for Laryngeal Cancer Patients N/A
Recruiting NCT05857202 - Oxidative Stress and Inflammation Biomarkers in Surgically Treated Patients With Laryngeal Cancer
Recruiting NCT06077643 - Workshops and Exchange Groups for Laryngectomized Patients
Not yet recruiting NCT06137378 - European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] Phase 2
Active, not recruiting NCT02586207 - Pembrolizumab in Combination With CRT for LA-SCCHN Phase 1
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Recruiting NCT05375266 - Immune Biomarker Study for Head and Neck Cancer
Completed NCT03134976 - Wound Complications in Head and Neck Surgery
Recruiting NCT04650919 - Aortic Laryngeal Rehabilitation Graft N/A
Recruiting NCT05830240 - A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer Early Phase 1
Terminated NCT02437513 - NewBreez for Airway Protection in Head and Neck Cancer Patients With Chronic Aspiration N/A
Completed NCT01332682 - Resistance Training and Physical Functioning in Head and Neck Cancer Patients Phase 1
Terminated NCT00011492 - Patient Evaluation for Head and Neck Surgery Branch Studies
Recruiting NCT05349487 - SpeakFree Heat and Moisture Exchanger (HME) N/A
Completed NCT00467948 - Comparison of 2 Cefazolin Prophylactic Protocol in Laryngectomy Patients Phase 3
Recruiting NCT06024980 - Using the Subglottic Pressure to Predict the Dysphagia After Partial Laryngectomy N/A
Recruiting NCT03747783 - Nomograms to Precisely Predict Conditional Risk of Survival for Patients With Laryngeal Cancer